Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis
Non–small cell lung cancer (NSCLC) represents almost 85% of total diagnosed lung cancer.
Studies have shown that combination of DNA methyltransferase (DNMT) and histone
deacetylase (HDAC) inhibitors is effective against various cancers, including lung cancer.
However, optimizing the synergistic dose regime is very difficult and involves adverse side
effects. Therefore, in this study, we have shown that cucurbitacin B (CuB), a single bioactive
triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 …
Studies have shown that combination of DNA methyltransferase (DNMT) and histone
deacetylase (HDAC) inhibitors is effective against various cancers, including lung cancer.
However, optimizing the synergistic dose regime is very difficult and involves adverse side
effects. Therefore, in this study, we have shown that cucurbitacin B (CuB), a single bioactive
triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 …
Cucurbitacin B alters the expression of tumor-related genes by epigenetic modifications in NSCLC and inhibits NNK-induced lung tumorigenesis.
SS Samriddhi Shukla, SK Sajid Khan… - 2015 - cabidigitallibrary.org
Non-small cell lung cancer (NSCLC) represents almost 85% of total diagnosed lung cancer.
Studies have shown that combination of DNA methyltransferase (DNMT) and histone
deacetylase (HDAC) inhibitors is effective against various cancers, including lung cancer.
However, optimizing the synergistic dose regime is very difficult and involves adverse side
effects. Therefore, in this study, we have shown that cucurbitacin B (CuB), a single bioactive
triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 …
Studies have shown that combination of DNA methyltransferase (DNMT) and histone
deacetylase (HDAC) inhibitors is effective against various cancers, including lung cancer.
However, optimizing the synergistic dose regime is very difficult and involves adverse side
effects. Therefore, in this study, we have shown that cucurbitacin B (CuB), a single bioactive
triterpenoid compound, inhibits both DNMTs and HDACs starting at a very low dose of 60 …
以上显示的是最相近的搜索结果。 查看全部搜索结果